Cargando…
PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
Autores principales: | Mihailova, D, Varbanova, B, Stefanov, S, Teltcharova, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043830/ http://dx.doi.org/10.1186/1546-0096-11-S2-P51 |
Ejemplares similares
-
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013) -
PReS-FINAL-2254: Is it systemic JIA or post infectious illness?
por: Guddeti, P, et al.
Publicado: (2013) -
PReS-FINAL-1007: Regulatory T cells functional specialization in JIA
por: Mijnheer, G, et al.
Publicado: (2013) -
PReS-FINAL-2057: Systemic onset JIA with coronary artery dilatation
por: Aktay Ayaz, N, et al.
Publicado: (2013) -
PReS-FINAL-2198: Insufficient efficacy of tocilizumab therapy in children with Castleman's disease
por: Kozlova, A, et al.
Publicado: (2013)